GoodRx vs Hippo Which Is Stronger?

GoodRx and Hippo are two companies operating in the healthcare industry, but with very different focuses. GoodRx is a technology company that provides a platform for consumers to compare drug prices and save money on their prescriptions. On the other hand, Hippo is a tech-enabled home insurance company that aims to simplify the process of obtaining home insurance for consumers. Both companies have seen significant growth and success in their respective fields, making them attractive investment opportunities for investors looking to capitalize on the evolving healthcare and insurance markets.

GoodRx or Hippo?

When comparing GoodRx and Hippo, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between GoodRx and Hippo.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. GoodRx has a dividend yield of -%, while Hippo has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. GoodRx reports a 5-year dividend growth of 0.00% year and a payout ratio of -55.33%. On the other hand, Hippo reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with GoodRx P/E ratio at -235.70 and Hippo's P/E ratio at -5.66. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. GoodRx P/B ratio is 2.68 while Hippo's P/B ratio is 2.20.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, GoodRx has seen a 5-year revenue growth of 1.61%, while Hippo's is -0.11%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with GoodRx's ROE at -1.15% and Hippo's ROE at -36.86%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $4.88 for GoodRx and $28.44 for Hippo. Over the past year, GoodRx's prices ranged from $4.09 to $9.26, with a yearly change of 126.41%. Hippo's prices fluctuated between $7.75 and $34.24, with a yearly change of 341.81%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.